C2N Diagnostics LLC (C2N Diagnostics) is a protein diagnostic and therapeutic discovery company that offers progressive neurodegeneration solutions. The company develops tools and assays for clinical drug development, preclinical drug discovery and early detection and assessment of neurodegenerative disorders. It offers products such as SILK-Ab and SISAQ-Ab assays. C2N Diagnostics' products are used for the measurement of kinetics, or in vivo metabolism, and absolute quantitation of brain derived proteins. The company also develops products used in the treatment of Huntington’s disease, Parkinson's disease, brain injury, amyotrophic lateral sclerosis and schizophrenia, among others. C2N Diagnostics is headquartered in St. Louis, Missouri, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
The report analyzes all pipeline products in development for the company C2N Diagnostics LLC
The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
The report provides detailed description of products in development, technical specification and functions
The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
To formulate effective Research & Development strategies
Develop market-entry and market expansion strategies
Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note:Some sections may be missing if data is unavailable for the company
C2N Diagnostics LLC Company Overview
C2N Diagnostics LLC Company Snapshot
C2N Diagnostics LLC Pipeline Products and Ongoing Clinical Trials Overview
C2N Diagnostics LLC – Pipeline Analysis Overview
C2N Diagnostics LLC - Key Facts
C2N Diagnostics LLC - Major Products and Services
C2N Diagnostics LLC Pipeline Products by Development Stage
C2N Diagnostics LLC Ongoing Clinical Trials by Trial Status
C2N Diagnostics LLC Pipeline Products Overview
Multi-Analyte Combination Assay
Multi-Analyte Combination Assay Product Overview
p-tau217 Blood Test
p-tau217 Blood Test Product Overview
p-tau217 Blood Test Clinical Trial
PrecivityAD2 Blood Test
PrecivityAD2 Blood Test Product Overview
PrecivityAD2 Blood Test Clinical Trial
C2N Diagnostics LLC - Key Competitors
C2N Diagnostics LLC - Key Employees
C2N Diagnostics LLC - Locations And Subsidiaries
Head Office
Recent Developments
C2N Diagnostics LLC, Recent Developments
Mar 18, 2024: New Research shows the PrecivityAD2 Blood Test has High Accuracy Compared to Amyloid PET Scans in Individuals with Cognitive Impairment
Mar 06, 2024: C2N Diagnostics, LLC Announces Investment From Eisai Inc.
Mar 05, 2024: Eisai Invests in C2N to Support Simplifying the Diagnosis of Early Alzheimer’s Disease to Better Serve Patients
Feb 21, 2024: Alzheimer’s blood test performs as well as FDA-approved spinal fluid tests
Nov 16, 2023: Researchers Identify New Cost Savings and Accuracy of C2N Diagnostics’ Blood Tests to Enable Healthcare Providers to Better Identify Alzheimer’s Disease
Nov 08, 2023: C2N’s Precivity blood biomarker test shows promise in Alzheimer’s screening
Nov 07, 2023: New Research Shows High Accuracy of Precivity Blood Biomarkers in the Evaluation of Brain Amyloid in Pre-Clinical Alzheimer's Disease
Oct 25, 2023: C2N Diagnostics Introduces Next-Generation Fluid Biomarker to the Field of Alzheimer’s Disease: Test to Help Researchers Track Neurofibrillary “Tau” Tangle Pathology
Oct 16, 2023: EISAI TO PRESENT data on PrecivityAD2 Blood Test at CTAD conference
Sep 21, 2023: On World Alzheimer’s Day, C2N Diagnostics’ PrecivityAD2 Blood Test Expands Reach